DK1541197T3 - Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser - Google Patents

Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser

Info

Publication number
DK1541197T3
DK1541197T3 DK04025035T DK04025035T DK1541197T3 DK 1541197 T3 DK1541197 T3 DK 1541197T3 DK 04025035 T DK04025035 T DK 04025035T DK 04025035 T DK04025035 T DK 04025035T DK 1541197 T3 DK1541197 T3 DK 1541197T3
Authority
DK
Denmark
Prior art keywords
compounds
agonistic
antagonistic
treatment
inverse
Prior art date
Application number
DK04025035T
Other languages
Danish (da)
English (en)
Inventor
Erik Buntinx
Original Assignee
Pharmaneuroboost N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03447279A external-priority patent/EP1547650A1/en
Priority claimed from EP04447066A external-priority patent/EP1576985A1/en
Application filed by Pharmaneuroboost N V filed Critical Pharmaneuroboost N V
Application granted granted Critical
Publication of DK1541197T3 publication Critical patent/DK1541197T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK04025035T 2003-12-02 2004-10-21 Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser DK1541197T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03447279A EP1547650A1 (en) 2003-12-02 2003-12-02 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04447001 2004-01-05
EP04447066A EP1576985A1 (en) 2004-03-18 2004-03-18 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists

Publications (1)

Publication Number Publication Date
DK1541197T3 true DK1541197T3 (da) 2009-06-15

Family

ID=40490565

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04025035T DK1541197T3 (da) 2003-12-02 2004-10-21 Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser

Country Status (10)

Country Link
EP (1) EP1541197B8 (pt)
JP (1) JP4571485B2 (pt)
AT (1) ATE425752T1 (pt)
CY (1) CY1110316T1 (pt)
DE (1) DE602004020042D1 (pt)
DK (1) DK1541197T3 (pt)
ES (1) ES2323269T3 (pt)
PL (1) PL1541197T3 (pt)
PT (1) PT1541197E (pt)
SI (1) SI1541197T1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP4571645B2 (ja) * 2003-12-02 2010-10-27 ファルマニューロブースト エン.フェー. D4および5−ht2aアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
GB0417702D0 (en) * 2004-08-09 2004-09-08 Merck Sharp & Dohme New uses
WO2006025516A1 (ja) * 2004-09-03 2006-03-09 Dainippon Sumitomo Pharma Co., Ltd. ペロスピロン経皮投与用医薬組成物
EP1830844A1 (en) * 2004-12-27 2007-09-12 Alpha 2 Pharmaceutical AB Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
EP2258359A3 (en) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2007258553A1 (en) * 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
MX2011002177A (es) * 2008-09-04 2011-04-12 Neurosearch As Metodo para combatir efectos adversos que surgen del tratamiento antipsicotico.
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
EP2236138A1 (en) * 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood and anxiety disorders
WO2011069075A2 (en) * 2009-12-04 2011-06-09 Grant Jon E Treating impulse control disorders with catechol-o- methyl-transferase inhibitors
WO2021139874A1 (en) * 2020-01-06 2021-07-15 Anima Cognitive disorder prevention and therapy
CN113181183A (zh) * 2021-05-20 2021-07-30 桂林医学院 卡麦角林在制备治疗焦虑障碍的药物组合物中的应用
CN114797036B (zh) * 2022-06-27 2022-09-27 深圳市心流科技有限公司 一种专注力训练方案制定方法、装置、设备及存储介质

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4039631A1 (de) * 1990-12-12 1992-06-17 Troponwerke Gmbh & Co Kg Neuroprotektive kombination
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
JP4571645B2 (ja) * 2003-12-02 2010-10-27 ファルマニューロブースト エン.フェー. D4および5−ht2aアンタゴニスト、逆アゴニストまたは部分アゴニストの使用

Also Published As

Publication number Publication date
ATE425752T1 (de) 2009-04-15
EP1541197A1 (en) 2005-06-15
CY1110316T1 (el) 2015-01-14
JP4571485B2 (ja) 2010-10-27
ES2323269T3 (es) 2009-07-10
EP1541197B1 (en) 2009-03-18
JP2005194263A (ja) 2005-07-21
PT1541197E (pt) 2009-06-04
PL1541197T3 (pl) 2009-10-30
DE602004020042D1 (de) 2009-04-30
SI1541197T1 (sl) 2009-08-31
EP1541197B8 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
CY1110316T1 (el) Χρηση πιπαμπερονης και ενος sndri, snri ή ssri για την θεραπεια διαταραχων ψυχικης διαθεσης ή αγχους
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
DE60327745D1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
CY1111197T1 (el) Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων
BR0307058A (pt) N-óxidos de derivados de n-fenil-2-pirimidina-amina
ATE479655T1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DK1758860T3 (da) Mættede og umættede 3-pyridylbenzocykloalkylmethylaminer til behandling af smerter, depressioner og angsttilstande
DK1730147T3 (da) Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser til behandling af fedme
EA200601279A1 (ru) Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
UA96277C2 (en) Benzimidazole derivatives
SE0403171D0 (sv) New compounds
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
AR046705A1 (es) Pirido-7-pirimidin-7-onas substituidas con hidroxialquilo
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
SV2006002192A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa ie
ATE391710T1 (de) Substituierte azetidinverbindungen als cyclooxigenase-1-cyclooxygenase-2-inhibitoren und deren herstellung und verwendung als medikament
SE0403118D0 (sv) New compounds 2